Once considered to be no more than “skin deep,” psoriasis is now recognized as a chronic, multisystemic, inflammatory immune disorder, with combined physical and psychologic effects greater than those of heart failure and chronic lung disease. Fortunately, modern therapies now offer the prospect of 90% or even 100% clearance of the skin for sustained periods of time. This activity will review current targets for skin clearance; the need to screen for comorbidities such as cardiovascular (CV) disease, depression, and psoriatic arthritis (PsA); and the efficacy and safety of traditional and novel therapies for both psoriasis and PsA.
Interactive clinical review and case study
After completing this activity, participants should be better able to:
- Summarize National Psoriasis Foundation (NPF) targets and current recommendations for when to screen patients with psoriatic disease for CV risk factors
- Evaluate treatment plans for psoriasis and PsA using novel therapies according to efficacy rates, safety profiles, and dosing regimens
- Implement screening for PsA and depression and other strategies for the long-term care of patients with psoriatic disease
NPs and PAs
CNE Credit Designation Statement
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Practicing Clinicians Exchange.
Contact hours: 1.00, which are eligible for 1.00 pharmacology credit
Course director: Jason Worcester, MD, Boston University School of Medicine
CNE course advisor: Claire Murphy, MSN, NP-C, Boston University School of Medicine
AAPA Credit Designation Statement
In support of improving patient care, this activity has been planned and implemented by Continuing Education Alliance and Boston University. Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until November 11, 2020. PAs should only claim credit commensurate with the extent of their participation.
This activity was developed from a series of programs cosupported by educational grants from Astellas Pharma, Inc.; Biogen; Genentech; Gilead Sciences, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk, Inc.
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
The opinions or views expressed in this continuing education activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the American Academy of Physician Assistants, Boston University School of Medicine, Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices is being discussed.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration.
Dr Kucera: consultant/honoraria: AbbVie, Celgene, Leo, Mayne, Novartis, Ortho, Pfizer, Sun Pharma.
The Planning Committee for this activity included Claire Murphy, MSN, NP-C, Carmela A. Townsend, DNP, MS/MBA, RN, Jason Worcester, MD, Jody Walker, MS, and Julie L. White, MS, of Boston University School of Medicine; and Ruth Cohen, Craig Borders, and Warren Beckman of Practicing Clinicians Exchange. None of the aforementioned members of the Planning Committee have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the content
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: November 12, 2019
Expiration date: November 11, 2020
Any internet connected computer or mobile device with any of the following browsers: Internet Explorer, Google Chrome, Mozilla Firefox, Safari.
© 2019 Practicing Clinicians Exchange. All Rights Reserved. CPCE95219-7I